[PDF] Human rights guidelines for pharmaceutical companies in relation to access to medicines: The sexual and reproductive health context

Author: Rajat Khosla & Paul Hunt, Human Rights Centre, University of Essex, Published on: 3 March 2009

The application of human rights may vary from one type of actor to another…[T]he logic of human rights will inevitably lead to their application, in one form or another, to non-State actors…This briefing examines the issue of access to medicines in the context of sexual and reproductive health…[It] considers the responsibilities of pharmaceutical companies for enhancing access to medicines…[T]he Guidelines are grouped by themes, such as transparency, management, monitoring and accountability, pricing and ethical marketing. Each theme is followed by a brief Commentary…The Guidelines are based on human rights principles that are enshrined in the Universal Declaration of Human Rights. [refers to Abbott Laboratories, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Novartis, NovoNordisk, Merck & Co.]

Read the full post here

Related companies: Abbott Laboratories Boehringer Ingelheim Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline Hoffmann-La Roche (part of Roche) Merck Novartis Novo Group Novo Nordisk (part of Novo Group) Roche